NASDAQ:CNTA Centessa Pharmaceuticals (CNTA) Stock Forecast, Price & News $5.80 -0.67 (-10.36%) (As of 01:28 PM ET) Add Compare Share Share Today's Range$5.18▼$6.4050-Day Range$6.06▼$7.9752-Week Range$3.00▼$8.65Volume89,259 shsAverage Volume155,092 shsMarket Capitalization$564.92 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Centessa Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside38.2% Upside$8.50 Price TargetShort InterestBearish2.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$235,774 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.74) to ($1.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector575th out of 969 stocksPharmaceutical Preparations Industry275th out of 453 stocks 3.3 Analyst's Opinion Consensus RatingCentessa Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.50, Centessa Pharmaceuticals has a forecasted upside of 38.2% from its current price of $6.15.Amount of Analyst CoverageCentessa Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.30% of the float of Centessa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCentessa Pharmaceuticals has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Centessa Pharmaceuticals has recently increased by 3.08%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCentessa Pharmaceuticals does not currently pay a dividend.Dividend GrowthCentessa Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CNTA. Previous Next 2.7 News and Social Media Coverage News SentimentCentessa Pharmaceuticals has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Centessa Pharmaceuticals this week, compared to 1 article on an average week.MarketBeat Follows4 people have added Centessa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Centessa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $235,774.00 in company stock.Percentage Held by Insiders11.54% of the stock of Centessa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions73.92% of the stock of Centessa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Centessa Pharmaceuticals are expected to decrease in the coming year, from ($1.74) to ($1.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Centessa Pharmaceuticals is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Centessa Pharmaceuticals is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentessa Pharmaceuticals has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Centessa Pharmaceuticals (NASDAQ:CNTA) StockCentessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.Read More CNTA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNTA Stock News HeadlinesSeptember 25, 2023 | americanbankingnews.comInsider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) SVP Sells 37,484 Shares of StockSeptember 24, 2023 | americanbankingnews.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 3.8% on Insider SellingOctober 2, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 1, 2023 | msn.comCentessa Pharmaceuticals plc - ADR (CNTA) Price Target Increased by 15.30% to 8.33August 31, 2023 | finance.yahoo.comCentessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceAugust 31, 2023 | finance.yahoo.comCentessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceAugust 23, 2023 | finance.yahoo.comCentessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep CongressAugust 17, 2023 | msn.comCentessa Pharmaceuticals: Pipeline Progresses As PRESent-2 InitiatedOctober 2, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!August 16, 2023 | msn.comGuggenheim Maintains Centessa Pharmaceuticals plc - ADR (CNTA) Buy RecommendationAugust 16, 2023 | msn.comSVB Securities Maintains Centessa Pharmaceuticals plc - ADR (CNTA) Outperform RecommendationAugust 15, 2023 | markets.businessinsider.comWhere Centessa Pharmaceuticals Stands With AnalystsAugust 14, 2023 | finance.yahoo.comCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023July 10, 2023 | finance.yahoo.comCentessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without InhibitorsJuly 6, 2023 | msn.comCentessa Pharmaceuticals plc - ADR (CNTA) Price Target Increased by 8.76% to 6.55June 22, 2023 | msn.comEvercore ISI Group Initiates Coverage of Centessa Pharmaceuticals plc - ADR (CNTA) with Outperform RecommendationJune 13, 2023 | msn.comGuggenheim Initiates Coverage of Centessa Pharmaceuticals plc - ADR (CNTA) with Buy RecommendationMay 23, 2023 | finanznachrichten.deCentessa Pharmaceuticals plc: Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia BMay 22, 2023 | markets.businessinsider.comCentessa Pharma Announces FDA's Decision To Grant Fast Track Designation For SerpinPCMay 22, 2023 | finance.yahoo.comCentessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia BMay 22, 2023 | seekingalpha.comCentessa Pharmaceuticals: Highly Diversified With Decent Cash, Good Data, No Near-Term CatalystsMay 15, 2023 | msn.comGoldman Sachs Maintains Centessa Pharmaceuticals plc - ADR (CNTA) Neutral RecommendationMay 12, 2023 | msn.comCentessa Pharmaceuticals: Q1 Earnings InsightsMay 12, 2023 | finance.yahoo.comCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023April 27, 2023 | finance.yahoo.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) most popular amongst private equity firms who own 42% of the shares, institutions hold 22%April 1, 2023 | seekingalpha.comCentessa Pharmaceuticals GAAP EPS of -$0.45 misses by $0.01March 30, 2023 | finance.yahoo.comCentessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022See More Headlines Receive CNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTA Company Calendar Last Earnings8/14/2023Today10/02/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CNTA CUSIPN/A CIK1847903 Webwww.centessa.com Phone44-73-9178-9784FaxN/AEmployees64Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.50 High Stock Price Forecast$15.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+38.2%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-216,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-54.00% Return on Assets-40.14% Debt Debt-to-Equity Ratio0.26 Current Ratio10.35 Quick Ratio10.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.55 per share Price / Book1.73Miscellaneous Outstanding Shares97,400,000Free Float86,163,000Market Cap$599.01 million OptionableNot Optionable Beta1.30 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Saurabh Saha M.D. (Age 46)Ph.D., CEO & Director Comp: $957.67kDr. Gregory M. Weinhoff M.B.A. (Age 52)M.D., MBA, Principal Accounting Officer & CFO Comp: $655kDr. David M. Chao Ph.D. (Age 55)Chief Admin. Officer Comp: $655kMs. Tia L. Bush (Age 52)Chief Technology & Quality Officer Ms. Kristen K. Sheppard Esq.J.D., Sr. VP of Investor Relations & Corp. CommunicationsMr. Iqbal J. Hussain L.L.B. (Age 42)Gen. Counsel, Chief Compliance Officer & Corp. Sec. Ms. Karen M. Anderson (Age 55)Chief People Officer Dr. Antoine Yver M.D. (Age 65)M.Sc., MSc, Exec. VP & Chairman of Devel. Dr. David John Grainger Ph.D. (Age 54)Chief Innovation Officer Dr. Harris L. Rotman Ph.D.Sr. VP of Regulatory AffairsMore ExecutivesKey CompetitorsEnliven TherapeuticsNASDAQ:ELVNAlpine Immune SciencesNASDAQ:ALPNPhathom PharmaceuticalsNASDAQ:PHATBicycle TherapeuticsNASDAQ:BCYCTyra BiosciencesNASDAQ:TYRAView All CompetitorsInsiders & InstitutionsHarris RotmanSold 37,484 sharesTotal: $235,774.36 ($6.29/share)Affinity Asset Advisors LLCBought 216,596 shares on 8/21/2023Ownership: 0.947%Point72 Asset Management L.P.Bought 235,906 shares on 8/15/2023Ownership: 2.104%Woodline Partners LPSold 48,230 shares on 8/15/2023Ownership: 0.719%Citadel Advisors LLCBought 5,300 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CNTA Stock - Frequently Asked Questions Should I buy or sell Centessa Pharmaceuticals stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Centessa Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CNTA shares. View CNTA analyst ratings or view top-rated stocks. What is Centessa Pharmaceuticals' stock price forecast for 2023? 7 equities research analysts have issued twelve-month target prices for Centessa Pharmaceuticals' shares. Their CNTA share price forecasts range from $4.00 to $15.00. On average, they anticipate the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 38.2% from the stock's current price. View analysts price targets for CNTA or view top-rated stocks among Wall Street analysts. How have CNTA shares performed in 2023? Centessa Pharmaceuticals' stock was trading at $3.10 at the beginning of the year. Since then, CNTA stock has increased by 98.4% and is now trading at $6.15. View the best growth stocks for 2023 here. When is Centessa Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our CNTA earnings forecast. How were Centessa Pharmaceuticals' earnings last quarter? Centessa Pharmaceuticals plc (NASDAQ:CNTA) issued its earnings results on Monday, August, 14th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.17. When did Centessa Pharmaceuticals IPO? (CNTA) raised $285 million in an initial public offering on Friday, May 28th 2021. The company issued 15,000,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers. What is Centessa Pharmaceuticals' stock symbol? Centessa Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNTA." How do I buy shares of Centessa Pharmaceuticals? Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Centessa Pharmaceuticals' stock price today? One share of CNTA stock can currently be purchased for approximately $6.15. How much money does Centessa Pharmaceuticals make? Centessa Pharmaceuticals (NASDAQ:CNTA) has a market capitalization of $599.01 million. The company earns $-216,210,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis. How can I contact Centessa Pharmaceuticals? Centessa Pharmaceuticals' mailing address is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. The official website for the company is www.centessa.com. The company can be reached via phone at 44-73-9178-9784 or via email at investorrelations@centessa.com. This page (NASDAQ:CNTA) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.